Study reveals less severity of Omicron BA.2, with fewer deaths and lower likelihood of hospitalizations and invasive procedures.
Explore This Research Lab
OverviewHepatorenal syndrome is complicated disease that results from a number of factors related to kidney and liver health. As a clinical and translational researcher, I work to understand current treatments for patients with this disease through two main pathways. First, we perform large epidemiologic analyses to optimize current therapies (such as vasoconstrictive medications, dialysis, or transjugular intrahepatic portosystemic shunt [TIPS] placement). Second, we are exploring new mechanisms and treatments for hepatorenal syndrome by examining regulators of vascular inflammation and endothelial cell dysfunction (such as Angiopoietin/Tie2 signaling). We have a growing biorepository of blood and urine samples of patients with hepatorenal syndrome that we use to improve testing and treatment of this population. We have ongoing collaborations between research centers in Nephrology and Hepatology at MGH, Beth Israel Deaconess Medical Center, and the Liver Unit at the University of Barcelona.
- Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. American Journal of Kidney Diseases. 2016; 68: 381-91.
- Allegretti AS, Vela Parada X, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI. Prognosis of patients with cirrhosis and acute kidney injury who initiate renal replacement therapy. Clinical Journal of the American Society of Nephrology. 2018; 13(1):16-25.
- Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi, M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT. Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology. 2019; 69(2):729-741.
- Director of Critical Care Nephrology - Department of Medicine
- Assistant Professor of Medicine - Harvard Medical School
Related News and Articles
- Oct | 12 | 2022
Research Spotlight: Microbial Bile Acid Metabolism Regulates Gut Barrier Integrity and Liver Injury and Could Be a New Treatment Target
Researchers looked at the impact of bacterial metabolism of host-produced bile acid (BA) metabolites on epithelial barrier integrity.
- Press Release
- Sep | 23 | 2022
The wrist-worn devices may identify patients who would benefit from stroke prevention therapies.
- Sep | 21 | 2022
Hydroxychloroquine dosing under 5 mg/kg/day is less effective in preventing lupus flares than higher dosing.
- Press Release
- Sep | 21 | 2022
Researchers from Mass General and colleagues have used an innovative organoid-on-a-chip model to identify new treatment targets for an inherited kidney disease that causes significant death and disability.
- Sep | 15 | 2022
Gout was more prevalent in adults self-reporting Black race during a recent 10-year period compared with their White counterparts.
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.